Effects of 26 weeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open-label, crossover, active-comparator FIORE trial.
Elena SuccurroPatrizia VizzaAnnalisa PapaSofia MiceliFrancesco CiconeTeresa Vanessa FiorentinoAngela SciacquaFrancesco AndreozziPierangelo VeltriGiuseppe Lucio CasciniGiorgio SestiPublished in: Diabetes, obesity & metabolism (2022)
The present study provides evidence that empagliflozin treatment in subjects with type 2 diabetes without coronary artery disease leads to a significant reduction in the myocardial glucose metabolic rate.
Keyphrases
- open label
- phase iii
- coronary artery disease
- phase ii
- clinical trial
- double blind
- left ventricular
- study protocol
- blood glucose
- blood pressure
- type diabetes
- randomized controlled trial
- phase ii study
- skeletal muscle
- cardiovascular events
- cardiovascular disease
- insulin resistance
- coronary artery bypass grafting
- gestational age
- glycemic control
- locally advanced